Evaluating Humoral Immunity Elicited by XBB.1.5 Monovalent COVID-19 Vaccine

Nguyenla, Xammy Huu; Bates, Timothy A.; Trank-Greene, Mila; Wahedi, Mastura; Tafesse, Fikadu G.; Curlin, Marcel

doi:10.3201/eid3006.240051

Advanced Search

Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

Advanced Search
Custom Query

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners. As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.

i

Evaluating Humoral Immunity Elicited by XBB.1.5 Monovalent COVID-19 Vaccine

6 2024
By Nguyenla, Xammy Huu ; Bates, Timothy A. ; Trank-Greene, Mila ; ...
http://dx.doi.org/10.3201/eid3006.240051
Source: Emerg Infect Dis. 2024; 30(6):1283-1285

[PDF-924.15 KB]

English

Details Supporting Files You May Also Like

Details:

Alternative Title:

Emerg Infect Dis
Personal Author:

Nguyenla, Xammy Huu ; Bates, Timothy A. ; Trank-Greene, Mila ; Wahedi, Mastura ; Tafesse, Fikadu G. ; ... More +

Nguyenla, Xammy Huu ; Bates, Timothy A. ; Trank-Greene, Mila ; Wahedi, Mastura ; Tafesse, Fikadu G. ; Curlin, Marcel Less -
Description:

Because novel SARS-CoV-2 variants continue to emerge, immunogenicity of XBB.1.5 monovalent vaccines against live clinical isolates needs to be evaluated. We report boosting of IgG (2.1×), IgA (1.5×), and total IgG/A/M (1.7×) targeting the spike receptor-binding domain and neutralizing titers against WA1 (2.2×), XBB.1.5 (7.4×), EG.5.1 (10.5×), and JN.1 (4.7×) variants.
Subjects:

[+]

Adult Antibodies, Neutralizing Antibodies, Viral COVID-19 COVID-19 Vaccines Female Humans Immunity, Humoral Immunogenicity, Vaccine Immunoglobulin A Immunoglobulin G SARS-CoV-2 Spike Glycoprotein, Coronavirus
Keywords:

[+]

Allergy And Immunology Antibodies Coronavirus Coronavirus Disease Respiratory Infections SARS Severe Acute Respiratory Syndrome Coronavirus 2 United States Vaccines Viruses
Source:

Emerg Infect Dis. 2024; 30(6):1283-1285
Pubmed ID:

38669121
Pubmed Central ID:

PMC11138983
Document Type:

Journal Article
Genre:

Research Letter
Volume:

30
Issue:

6
Collection(s):

Emerging Infectious Diseases
Main Document Checksum:

[+]

urn:sha256:c93762c026963de1020f6234c679d244717accc12c7d6537331b89274d7d1903
Download URL:

https://stacks.cdc.gov/view/cdc/156995/cdc_156995_DS1.pdf
File Type:

	24-0051-F.gif	gif
	24-0051-F.jpg	jpeg
	24-0051-Techapp-s1.pdf	pdf
	24-0051.nxml	xml

More +